Cutler Group LP Esperion Therapeutics, Inc. Transaction History

Cutler Group LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$1.46 - $7.3 $2,190 - $10,950	1,500 New	1,500 $2,000
Q1 2022 Apr 14, 2022	SELL	$3.34 - $5.56 $48,764 - $81,176	-14,600 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$4.81 - $11.92 $66,378 - $164,496	13,800 Added 1725.0%	14,600 $73,000
Q1 2021 Apr 26, 2021	SELL	$25.12 - $36.89 $2,512 - $3,689	-100 Reduced 11.11%	800 $22,000
Q3 2020 Oct 27, 2020	BUY	$31.18 - $52.71 $3,118 - $5,271	100 Added 12.5%	900 $33,000
Q2 2020 Jul 22, 2020	BUY	$30.04 - $51.31 $6,008 - $10,262	200 Added 33.33%	800 $41,000
Q1 2020 May 07, 2020	SELL	$27.44 - $73.84 $90,552 - $243,672	-3,300 Reduced 84.62%	600 $18,000
Q4 2019 Feb 06, 2020	BUY	$35.4 - $59.82 $67,260 - $113,658	1,900 Added 95.0%	3,900 $232,000
Q3 2019 Oct 28, 2019	BUY	$34.47 - $47.53 $20,682 - $28,518	600 Added 42.86%	2,000 $73,000
Q2 2019 Aug 09, 2019	SELL	$40.1 - $52.33 $40,100 - $52,330	-1,000 Reduced 41.67%	1,400 $65,000
Q1 2019 May 10, 2019	SELL	$40.11 - $53.57 $44,121 - $58,927	-1,100 Reduced 31.43%	2,400 $96,000
Q4 2018 Feb 05, 2019	BUY	$36.99 - $59.11 $22,194 - $35,466	600 Added 20.69%	3,500 $161,000
Q3 2018 Nov 07, 2018	SELL	$40.74 - $51.41 $32,592 - $41,128	-800 Reduced 21.62%	2,900 $128,000
Q1 2018 May 11, 2018	BUY	$65.94 - $80.76 $237,384 - $290,736	3,600 Added 3600.0%	3,700 $267,000
Q4 2017 Jan 17, 2018	SELL	$43.47 - $67.43 $72,421 - $112,338	-1,666 Reduced 94.34%	100 $6,000
Q3 2017 Oct 17, 2017	BUY	$43.8 - $52.77 $77,350 - $93,191	1,766	1,766 $88,000

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $156M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.